Latest news with #HealthyChina2030
Hamilton Spectator
21-07-2025
- Business
- Hamilton Spectator
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
BEIJING, July 21, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. ('Fangzhou' or the 'Company') ( a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. Fangzhou and Novo Nordisk Signed Collaboration Memorandum Fangzhou's founder, chairman, and CEO Dr. Xie Fangmin, and Christine Zhou, Novo Nordisk Senior Vice President & President of Region China, attended the signing ceremony. By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a 'disease-centered' approach to a 'health-centered' model, providing patients with higher quality and more convenient one-stop healthcare services. Dr. Xie Fangmin remarked, 'We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.' Christine Zhou said, 'With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments.' Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the 'Healthy China 2030' strategic objectives. About Fangzhou Inc. Fangzhou Inc. ( is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit . Media Contact For further inquiries or interviews, please reach out to: Xingwei Zhao, Associate Director of Public Relations Email: pr@ Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements A photo accompanying this announcement is available at
Yahoo
10-06-2025
- Business
- Yahoo
Global Clinical Workflow Management Software Market Projected to Reach USD USD 40,243 million by 2030., Growing at a 22.97% CAGR: MarkNtel Advisors - Leading key players (GE Healthcare, Oracle Health, Allscripts Healthcare Solutions, Siemens Healthineers, Koninklijke Philips N.V., McKesson Corporation and Others)
NEW DELHI, June 10, 2025 /PRNewswire/ -- The Global Clinical Workflow Management Software Market size is set to experience significant growth in the coming years. Valued at around USD 11,640 Million in 2024, it is expected to soar to nearly USD 40,243 Million by 2030, with a staggering annual growth rate of about 22.97%. This growth is attributed to several key factors. The rising number of chronic illnesses and an aging population are creating a pressing need for efficient healthcare management. Additionally, government efforts to enhance digital healthcare infrastructure are playing a crucial role. With a projected shortage of 12 million healthcare professionals by 2030, especially in rural areas, the demand for workflow management systems is more critical than ever. These solutions streamline patient care and reduce delays, addressing the gap left by a lack of skilled workers. Initiatives like the HITECH Act in the U.S. and Healthy China 2030 highlight the global push towards digital healthcare, providing essential support to this burgeoning market. Furthermore, there's an increasing need for cloud-based platforms to manage healthcare data effectively, given the volume of patient records that require organization and accessibility. However, high costs associated with software installation and maintenance present challenges. Despite this, the future looks bright for clinical workflow management as technology continues to evolve, making healthcare more efficient and responsive to patient needs. Interested User Can Get a FREE PDF sample of the report here - Global Clinical Workflow Management Software Market Statistics: Market Value in 2024: USD 11,640 Million Projected Valuation by 2030: USD 40,243 Million Forecast Period CAGR: 22.97% (2025–2030) Base Year: 2024 | Historical Years: 2020–2023 Leading Segment "By Product Type": Data Integration Solutions Leading Region: North America Market Dynamic - 1.) Clinical Workflow Management Software Industry Key Driver: Rising Patient Volume & Chronic Diseases - The surge in chronic diseases like diabetes, cancer, and kidney disorders is significantly driving demand for clinical workflow management software. With China reporting approximately 139 million diabetes cases and the WHO noting 20 million new cancer cases in 2022, managing the increasing patient volume becomes challenging. This need for efficient, autonomous remote patient management solutions is a crucial factor fueling the global growth of clinical workflow management software. 2.) Clinical Workflow Management Software Market Opportunity Supportive Regulatory Frameworks - Governments worldwide are promoting remote patient care and telemedicine to enhance healthcare services. The U.S. enacted the Full Year Continuing Appropriations and Extensions Act (2025), while India introduced the Ayushman Bharat Digital Mission. China's Healthy China 2030 pilot program and Qatar's Telemedicine Regulation further signify this trend. These supportive regulatory measures foster significant growth opportunities for clinical workflow management software by expanding digital and telehealth services. 3.) Clinical Workflow Management Software Sector Challenge Limited Skilled Professionals & High Costs - Many regions, particularly rural areas, face challenges in digitalization due to financial constraints and a lack of healthcare professionals. Countries like China, India, and Brazil show low adoption rates of digital healthcare systems. Additionally, the high costs of clinical management software, varying by region, further hinder market growth. For example, software pricing ranges from USD 200 in China and India to around USD 500 in Japan, making adoption difficult for many healthcare facilities. 4.) Clinical Workflow Management Software Market Trend Rise of Cloud-Based Workflow Management Systems - The healthcare sector is increasingly adopting cloud-based workflow management systems to efficiently handle vast amounts of digital health records. Companies like Allscripts and AthenaHealth have launched platforms that enhance electronic health record management. Additionally, automated systems like eCW V12 are shaping the market positively by improving data organization and scalability. This transition to cloud solutions represents a significant trend driving future growth in the clinical workflow management software market. For in-depth analysis, market data, and forecasts, access the complete study - Global Clinical Workflow Management Software Segmentation Analysis: By Product Type (Real-Time Communication Solutions, Data Integration Solutions, Workflow Automation Solutions, Enterprise Reporting and Analytics Solutions, Care Collaboration Solutions, Others) By End User (Hospitals, Ambulatory Care Centers, Clinics & Specialty Centers, Home Healthcare Providers) By Deployment (On-Premise, Cloud-Based) - Based on Product Type: Data Integration Solutions Holds the Largest Market Share of More Than 35% Hospitals are projected to lead the Clinical Workflow Management Software market, capturing around 65% of the overall share. This dominance stems from their capacity to handle a high volume of patients daily, necessitating advanced data management solutions. The increasing demand for early disease detection and improved treatment options further drives the need for efficient workflow systems within hospital settings. Furthermore, significant government investments aimed at upgrading hospital technologies are solidifying this segment's position in the market, making hospitals key players in healthcare innovation. Industry Recent Development: 2025: GE Healthcare launched a new cloud-based portfolio called Genesis Suite, designed to help healthcare providers store, access, and manage large volumes of medical images securely from anywhere. 2024: Infor, Inc. has launched the FHIR server, a modern, scalable solution built on HL7 FHIR standards to make clinical data more accessible at the point of care. Geographically, the Global Clinical Workflow Management Software Market expands across: North America South America Europe The Middle East & Africa Asia-Pacific - North America Holds the Largest Clinical Workflow Management Software Market Share of More Than 45% North America is the clear frontrunner in the Global Clinical Workflow Management Software Market, holding over 45% of the market share. The region is experiencing a growing elderly population, which has fueled the demand for remote and virtual patient care services, particularly as seniors are prone to chronic illnesses. In fact, approximately 78% of older adults in the U.S. suffer from long-term diseases. This trend pressures healthcare providers to increase remote monitoring capabilities, as many seniors prefer receiving care at home. The dominance of North America is further reinforced by the strong development of healthcare infrastructure and the widespread adoption of IT solutions in the healthcare sector. Government investments in healthcare advancements and technology are also contributing to this region's leadership in the global market, ensuring that North America remains at the forefront of clinical workflow management innovations. Schedule a Consultation with Our Experts! – Competitive Landscape: List of Emerging Clinical Workflow Management Software Companies Globally GE Healthcare Oracle Health Allscripts Healthcare Solutions Siemens Healthineers Koninklijke Philips N.V. McKesson Corporation NextGen Healthcare Athenahealth, Inc. eClinicalWorks Cisco Systems, Inc. Epic Systems Corporation Infor, Inc. Baxter International Inc. Ascom Holding AG Others Report – List of Tables Table 1: Market Size & Analysis By Revenue (USD Million) Table 2: Market Share & Analysis By Product Type Table 3: Real-Time Communication Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 4: Data Integration Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 5: Workflow Automation Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 6: Enterprise Reporting and Analytics Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 7: Care Collaboration Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 8: Hospitals- Market Size & Forecast 2020-2030 (USD Million) Table 9: Ambulatory Care Centers- Market Size & Forecast 2020-2030 (USD Million) Table 10: On-Premise- Market Size & Forecast 2020-2030 (USD Million) Table 11: Cloud-Based- Market Size & Forecast 2020-2030 (USD Million) Table 12: North America Clinical Workflow Management Software Market Share By End User Table 13: Europe Clinical Workflow Management Software Market Size By Country Table 14: Competitive Outlook of Market Leaders Table 15: Company Profiles Overview of Key Players Report - List of Figures Figure 1: Global Clinical Workflow Management Software Market Trends & Developments Figure 2: Growth Drivers of the Global Clinical Workflow Management Software Market Figure 3: Challenges Facing the Global Clinical Workflow Management Software Market Figure 4: Regulations, Policies & Standards in Clinical Workflow Management Figure 5: Market Size & Forecast 2020-2030 by Region Figure 6: North America Market Size & Analysis By End User Figure 7: South America Market Outlook by Revenue Figure 8: Europe Market Analysis by Product Type Figure 9: Key Strategic Imperatives for Growth in Clinical Workflow Management Figure 10: Competitive Landscape of Clinical Workflow Management Software Market Looking for Regional or country-specific reports on this market? Visit our website or simply fill out the inquiry form - About Us – MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others. We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others. Similar Topic – Global Gastroesophageal Reflux Disease (GERD) Device Market Research Report: Forecast (2025-2030) - The Global Gastroesophageal Reflux Disease Device Market size was valued at around USD 2.5 billion in 2024 and is expected to reach USD 3.03 billion in 2030. Along with this, the market is estimated to grow at a CAGR of around 3.24% during the forecast period, i.e., 2025-30 Global Minimally Invasive Gastrointestinal Surgical Systems Market Research Report: Forecast (2025-2030)- The Global Minimally Invasive Gastrointestinal Surgical Systems Market size was valued at around USD 6.63 billion in 2024 and is projected to reach USD 9.64 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 6.43% during the forecast period, i.e., 2025-30. Global Artificial Intelligence (AI) Enabled Medical Imaging Market Research Report: Forecast (2025-2030) - The Global Artificial Intelligence (AI) Enabled Medical Imaging Market size was valued at around USD 3.23 billion in 2023 & is projected to reach around USD 16.20 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 25.9% during the forecast period, i.e., 2025-30. Global Patient Scheduling Software Market Research Report: Forecast (2025-2030) - The Global Patient Scheduling Software Market size was valued at around USD 0.41 billion in 2024 & is estimated to grow at a CAGR of around 12.82% during the forecast period, i.e., 2025-30. By 2030, the market is expected to reach USD 1.52 billion. US Clinical Documentation Improvement Market Research Report: Forecast (2025-2030) - The US Clinical Documentation Improvement Market was valued at USD 2,519.731 million in 2024 and is projected to reach USD 3,953.104 million by 2030. Along with this, the market is estimated to grow at a CAGR of around 7.86% during the forecast period, 2025-30. US Ambulatory EHR Market Research Report: Forecast (2025-2030) - The US Ambulatory EHR Market size was valued at USD 3.18 billion in 2024. The market size is set to touch USD 7.84 billion in 2030 and is estimated to grow at a CAGR of around 5.3% during the forecast period, i.e., 2025-30. US Patient Referral Management Software Market Research Report: Forecast (2025-2030) - The US Patient Referral Management Software size was valued at USD 5.21 billion in 2024 and is expected to reach USD 12.34 billion in 2030. Contact:MarkNtel AdvisorsOffice No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, IndiaContact No: +91 8719999009Email: sales@ our Website: Source: Logo - View original content to download multimedia: SOURCE Markntel Advisors LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Global Clinical Workflow Management Software Market Projected to Reach USD USD 40,243 million by 2030., Growing at a 22.97% CAGR: MarkNtel Advisors - Leading key players (GE Healthcare, Oracle Health, Allscripts Healthcare Solutions, Siemens Healthineers, Koninklijke Philips N.V., McKesson Corporation and Others)
NEW DELHI, June 10, 2025 /PRNewswire/ -- The Global Clinical Workflow Management Software Market size is set to experience significant growth in the coming years. Valued at around USD 11,640 Million in 2024, it is expected to soar to nearly USD 40,243 Million by 2030, with a staggering annual growth rate of about 22.97%. This growth is attributed to several key factors. The rising number of chronic illnesses and an aging population are creating a pressing need for efficient healthcare management. Additionally, government efforts to enhance digital healthcare infrastructure are playing a crucial role. With a projected shortage of 12 million healthcare professionals by 2030, especially in rural areas, the demand for workflow management systems is more critical than ever. These solutions streamline patient care and reduce delays, addressing the gap left by a lack of skilled workers. Initiatives like the HITECH Act in the U.S. and Healthy China 2030 highlight the global push towards digital healthcare, providing essential support to this burgeoning market. Furthermore, there's an increasing need for cloud-based platforms to manage healthcare data effectively, given the volume of patient records that require organization and accessibility. However, high costs associated with software installation and maintenance present challenges. Despite this, the future looks bright for clinical workflow management as technology continues to evolve, making healthcare more efficient and responsive to patient needs. Interested User Can Get a FREE PDF sample of the report here - Global Clinical Workflow Management Software Market Statistics: Market Value in 2024: USD 11,640 Million Projected Valuation by 2030: USD 40,243 Million Forecast Period CAGR: 22.97% (2025–2030) Base Year: 2024 | Historical Years: 2020–2023 Leading Segment "By Product Type": Data Integration Solutions Leading Region: North America Market Dynamic - 1.) Clinical Workflow Management Software Industry Key Driver: Rising Patient Volume & Chronic Diseases - The surge in chronic diseases like diabetes, cancer, and kidney disorders is significantly driving demand for clinical workflow management software. With China reporting approximately 139 million diabetes cases and the WHO noting 20 million new cancer cases in 2022, managing the increasing patient volume becomes challenging. This need for efficient, autonomous remote patient management solutions is a crucial factor fueling the global growth of clinical workflow management software. 2.) Clinical Workflow Management Software Market Opportunity Supportive Regulatory Frameworks - Governments worldwide are promoting remote patient care and telemedicine to enhance healthcare services. The U.S. enacted the Full Year Continuing Appropriations and Extensions Act (2025), while India introduced the Ayushman Bharat Digital Mission. China's Healthy China 2030 pilot program and Qatar's Telemedicine Regulation further signify this trend. These supportive regulatory measures foster significant growth opportunities for clinical workflow management software by expanding digital and telehealth services. 3.) Clinical Workflow Management Software Sector Challenge Limited Skilled Professionals & High Costs - Many regions, particularly rural areas, face challenges in digitalization due to financial constraints and a lack of healthcare professionals. Countries like China, India, and Brazil show low adoption rates of digital healthcare systems. Additionally, the high costs of clinical management software, varying by region, further hinder market growth. For example, software pricing ranges from USD 200 in China and India to around USD 500 in Japan, making adoption difficult for many healthcare facilities. 4.) Clinical Workflow Management Software Market Trend Rise of Cloud-Based Workflow Management Systems - The healthcare sector is increasingly adopting cloud-based workflow management systems to efficiently handle vast amounts of digital health records. Companies like Allscripts and AthenaHealth have launched platforms that enhance electronic health record management. Additionally, automated systems like eCW V12 are shaping the market positively by improving data organization and scalability. This transition to cloud solutions represents a significant trend driving future growth in the clinical workflow management software market. For in-depth analysis, market data, and forecasts, access the complete study - Global Clinical Workflow Management Software Segmentation Analysis: By Product Type (Real-Time Communication Solutions, Data Integration Solutions, Workflow Automation Solutions, Enterprise Reporting and Analytics Solutions, Care Collaboration Solutions, Others) By End User (Hospitals, Ambulatory Care Centers, Clinics & Specialty Centers, Home Healthcare Providers) By Deployment (On-Premise, Cloud-Based) - Based on Product Type: Data Integration Solutions Holds the Largest Market Share of More Than 35% Hospitals are projected to lead the Clinical Workflow Management Software market, capturing around 65% of the overall share. This dominance stems from their capacity to handle a high volume of patients daily, necessitating advanced data management solutions. The increasing demand for early disease detection and improved treatment options further drives the need for efficient workflow systems within hospital settings. Furthermore, significant government investments aimed at upgrading hospital technologies are solidifying this segment's position in the market, making hospitals key players in healthcare innovation. Industry Recent Development: 2025: GE Healthcare launched a new cloud-based portfolio called Genesis Suite, designed to help healthcare providers store, access, and manage large volumes of medical images securely from anywhere. 2024: Infor, Inc. has launched the FHIR server, a modern, scalable solution built on HL7 FHIR standards to make clinical data more accessible at the point of care. Geographically, the Global Clinical Workflow Management Software Market expands across: North America South America Europe The Middle East & Africa Asia-Pacific - North America Holds the Largest Clinical Workflow Management Software Market Share of More Than 45% North America is the clear frontrunner in the Global Clinical Workflow Management Software Market, holding over 45% of the market share. The region is experiencing a growing elderly population, which has fueled the demand for remote and virtual patient care services, particularly as seniors are prone to chronic illnesses. In fact, approximately 78% of older adults in the U.S. suffer from long-term diseases. This trend pressures healthcare providers to increase remote monitoring capabilities, as many seniors prefer receiving care at home. The dominance of North America is further reinforced by the strong development of healthcare infrastructure and the widespread adoption of IT solutions in the healthcare sector. Government investments in healthcare advancements and technology are also contributing to this region's leadership in the global market, ensuring that North America remains at the forefront of clinical workflow management innovations. Schedule a Consultation with Our Experts! – Competitive Landscape: List of Emerging Clinical Workflow Management Software Companies Globally GE Healthcare Oracle Health Allscripts Healthcare Solutions Siemens Healthineers Koninklijke Philips N.V. McKesson Corporation NextGen Healthcare Athenahealth, Inc. eClinicalWorks Cisco Systems, Inc. Epic Systems Corporation Infor, Inc. Baxter International Inc. Ascom Holding AG Others Report – List of Tables Table 1: Market Size & Analysis By Revenue (USD Million) Table 2: Market Share & Analysis By Product Type Table 3: Real-Time Communication Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 4: Data Integration Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 5: Workflow Automation Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 6: Enterprise Reporting and Analytics Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 7: Care Collaboration Solutions- Market Size & Forecast 2020-2030 (USD Million) Table 8: Hospitals- Market Size & Forecast 2020-2030 (USD Million) Table 9: Ambulatory Care Centers- Market Size & Forecast 2020-2030 (USD Million) Table 10: On-Premise- Market Size & Forecast 2020-2030 (USD Million) Table 11: Cloud-Based- Market Size & Forecast 2020-2030 (USD Million) Table 12: North America Clinical Workflow Management Software Market Share By End User Table 13: Europe Clinical Workflow Management Software Market Size By Country Table 14: Competitive Outlook of Market Leaders Table 15: Company Profiles Overview of Key Players Report - List of Figures Figure 1: Global Clinical Workflow Management Software Market Trends & Developments Figure 2: Growth Drivers of the Global Clinical Workflow Management Software Market Figure 3: Challenges Facing the Global Clinical Workflow Management Software Market Figure 4: Regulations, Policies & Standards in Clinical Workflow Management Figure 5: Market Size & Forecast 2020-2030 by Region Figure 6: North America Market Size & Analysis By End User Figure 7: South America Market Outlook by Revenue Figure 8: Europe Market Analysis by Product Type Figure 9: Key Strategic Imperatives for Growth in Clinical Workflow Management Figure 10: Competitive Landscape of Clinical Workflow Management Software Market Looking for Regional or country-specific reports on this market? Visit our website or simply fill out the inquiry form - About Us – MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others. We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others. Similar Topic – Global Gastroesophageal Reflux Disease (GERD) Device Market Research Report: Forecast (2025-2030) - The Global Gastroesophageal Reflux Disease Device Market size was valued at around USD 2.5 billion in 2024 and is expected to reach USD 3.03 billion in 2030. Along with this, the market is estimated to grow at a CAGR of around 3.24% during the forecast period, i.e., 2025-30 Global Minimally Invasive Gastrointestinal Surgical Systems Market Research Report: Forecast (2025-2030)- The Global Minimally Invasive Gastrointestinal Surgical Systems Market size was valued at around USD 6.63 billion in 2024 and is projected to reach USD 9.64 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 6.43% during the forecast period, i.e., 2025-30. Global Artificial Intelligence (AI) Enabled Medical Imaging Market Research Report: Forecast (2025-2030) - The Global Artificial Intelligence (AI) Enabled Medical Imaging Market size was valued at around USD 3.23 billion in 2023 & is projected to reach around USD 16.20 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 25.9% during the forecast period, i.e., 2025-30. Global Patient Scheduling Software Market Research Report: Forecast (2025-2030) - The Global Patient Scheduling Software Market size was valued at around USD 0.41 billion in 2024 & is estimated to grow at a CAGR of around 12.82% during the forecast period, i.e., 2025-30. By 2030, the market is expected to reach USD 1.52 billion. US Clinical Documentation Improvement Market Research Report: Forecast (2025-2030) - The US Clinical Documentation Improvement Market was valued at USD 2,519.731 million in 2024 and is projected to reach USD 3,953.104 million by 2030. Along with this, the market is estimated to grow at a CAGR of around 7.86% during the forecast period, 2025-30. US Ambulatory EHR Market Research Report: Forecast (2025-2030) - The US Ambulatory EHR Market size was valued at USD 3.18 billion in 2024. The market size is set to touch USD 7.84 billion in 2030 and is estimated to grow at a CAGR of around 5.3% during the forecast period, i.e., 2025-30. US Patient Referral Management Software Market Research Report: Forecast (2025-2030) - The US Patient Referral Management Software size was valued at USD 5.21 billion in 2024 and is expected to reach USD 12.34 billion in 2030. Contact:MarkNtel AdvisorsOffice No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, IndiaContact No: +91 8719999009Email: sales@ our Website: Source: Logo - View original content to download multimedia: SOURCE Markntel Advisors LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Sydney Morning Herald
02-06-2025
- Business
- Sydney Morning Herald
China's latest boom is sounding alarm bells in America
It marked a watershed moment for the pharmaceutical sector, which had long written off China as a nation that excelled in drug manufacturing and 'copycat' treatments but not medicine discovery. Akeso's debut on the world stage has been described as a 'DeepSeek' moment for the industry – a reference to the sudden emergence of a highly advanced AI chatbot out of China earlier this year, which took US tech giants by surprise and wiped close to $US1 trillion ($1.5 trillion) off global stock markets. Summit's shares are up more than 600 per cent since first announcing the lung cancer trial results. 'The two large innovators in our industry today are the US and China,' Sir Pascal Soriot, the boss of AstraZeneca, said in March. 'China is, I think over the next five to 10 years, going to emerge as really a driving force for innovation in our sector.' It sets the stage for a growing tussle between the US and China over the future of drug development. Donald Trump has been clear that he wants pharmaceutical giants to be investing more in America. Biopharmaceutical companies and their suppliers account for 4.9 million jobs and are worth around $US1.65 trillion ($2.6 trillion) to the US. However, drug companies are increasingly turning east when it comes to investing in new drugs and clinical trials. Not only is China becoming an easier place to research and create new drugs, but the Trump administration is also shaking faith in the US. Vaccine sceptic health secretary Robert F Kennedy Jr has prompted much anxiety in the industry. By contrast, China is 'very business friendly and stable' Novartis boss Vas Narasimhan said in May. Drugs boom Beijing has been attempting to win more pharma investment for years – and specifically attempting to boost funding for drug innovation. Drug discovery was a key pillar of the 'Healthy China 2030″ strategy unveiled in 2016, aimed at helping the country cope with its ageing population. Loading The focus has already paid dividends. Over the past three years alone, the number of Chinese drugs in development has doubled to 4,391. Almost half are either novel drugs or something known as a 'fast-follower', where treatments are quickly developed on the back of breakthroughs by rivals. According to Barclays, the number of so-called 'first-in-class' drugs under development in China rose to around 120 last year, having been in the single digits in 2015. First-in-class essentially measures the level of innovation by looking at the highest development stage a drug has reached and the earliest time it reached that stage. The growth in China is unmatched. While the US, which has long been regarded as the world leader in drug discovery, has more first-in-class drugs in development, at 151, the growth rate has been much slower. 'The shift isn't incremental, it's tectonic,' says Abhishek Jha, the founder of life sciences data company Elucidata. One crucial part of Beijing's push to drive more drug discovery has been speeding up clinical trials. In China, regulators allow businesses to get studies up and running quicker, and then update them as they progress. This can provide early data on new drugs, which is a major draw for multinational companies looking for novel treatments that show signs of working well. It has sparked a boom in studies taking place in China. According to figures from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), China accounted for around 18 per cent of clinical trials sponsored by companies in 2023 compared to just 5 per cent in 2013. Meanwhile, the US proportion has dipped from 28 per cent to 23 per cent. Clinical trial enrolment in China is surging, with around 40 per cent now having more than 100 participants. Bitter pill Fewer regulatory barriers are just one of a number of reasons pharma companies are turning to China. Workers, too, are less averse to working unsociable hours than they would be in Western nations. Shirley Chen, a Barclays analyst, says: 'Chinese scientists may be happier to accept very long work hours and people like hospital personnel [where trials take place] are actually okay to do night shifts.' Major drug giants are now scouring China for potential deals. The likes of GSK, AstraZeneca and Merck have all struck deals worth more than $US1 billion to get the rights to develop and sell Chinese drugs outside the country. The rise of China's pharmaceutical industry has started to raise alarm bells in the US. Trump may be focused on returning manufacturing jobs to the US, yet some say he should be concerned that more high-quality jobs and research posts are starting to drift to China. 'Five years ago, US pharmaceutical companies didn't license any new drugs from China,' Scott Gottlied, the former Food and Drug Administration commissioner, wrote earlier this month. 'By 2024, one third of their new compounds were coming from Chinese biotechnology firms.' He warned that the shift of clinical trials to Asia could undermine innovation in the US as companies choose to 'divert funds that might otherwise bolster innovation hubs such as Boston's Kendall Square or North Carolina's Research Triangle'. Loading 'The US biotechnology industry was the world's envy, but if we're not careful, every drug could be made in China.' While Trump exempted most countries' pharmaceutical industries from tariffs in his 'liberation day' blitz, China was not spared. That means physically manufacturing drugs for the US in China is out of the question, for now at least.
The Age
02-06-2025
- Business
- The Age
China's latest boom is sounding alarm bells in America
It marked a watershed moment for the pharmaceutical sector, which had long written off China as a nation that excelled in drug manufacturing and 'copycat' treatments but not medicine discovery. Akeso's debut on the world stage has been described as a 'DeepSeek' moment for the industry – a reference to the sudden emergence of a highly advanced AI chatbot out of China earlier this year, which took US tech giants by surprise and wiped close to $US1 trillion ($1.5 trillion) off global stock markets. Summit's shares are up more than 600 per cent since first announcing the lung cancer trial results. 'The two large innovators in our industry today are the US and China,' Sir Pascal Soriot, the boss of AstraZeneca, said in March. 'China is, I think over the next five to 10 years, going to emerge as really a driving force for innovation in our sector.' It sets the stage for a growing tussle between the US and China over the future of drug development. Donald Trump has been clear that he wants pharmaceutical giants to be investing more in America. Biopharmaceutical companies and their suppliers account for 4.9 million jobs and are worth around $US1.65 trillion ($2.6 trillion) to the US. However, drug companies are increasingly turning east when it comes to investing in new drugs and clinical trials. Not only is China becoming an easier place to research and create new drugs, but the Trump administration is also shaking faith in the US. Vaccine sceptic health secretary Robert F Kennedy Jr has prompted much anxiety in the industry. By contrast, China is 'very business friendly and stable' Novartis boss Vas Narasimhan said in May. Drugs boom Beijing has been attempting to win more pharma investment for years – and specifically attempting to boost funding for drug innovation. Drug discovery was a key pillar of the 'Healthy China 2030″ strategy unveiled in 2016, aimed at helping the country cope with its ageing population. Loading The focus has already paid dividends. Over the past three years alone, the number of Chinese drugs in development has doubled to 4,391. Almost half are either novel drugs or something known as a 'fast-follower', where treatments are quickly developed on the back of breakthroughs by rivals. According to Barclays, the number of so-called 'first-in-class' drugs under development in China rose to around 120 last year, having been in the single digits in 2015. First-in-class essentially measures the level of innovation by looking at the highest development stage a drug has reached and the earliest time it reached that stage. The growth in China is unmatched. While the US, which has long been regarded as the world leader in drug discovery, has more first-in-class drugs in development, at 151, the growth rate has been much slower. 'The shift isn't incremental, it's tectonic,' says Abhishek Jha, the founder of life sciences data company Elucidata. One crucial part of Beijing's push to drive more drug discovery has been speeding up clinical trials. In China, regulators allow businesses to get studies up and running quicker, and then update them as they progress. This can provide early data on new drugs, which is a major draw for multinational companies looking for novel treatments that show signs of working well. It has sparked a boom in studies taking place in China. According to figures from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), China accounted for around 18 per cent of clinical trials sponsored by companies in 2023 compared to just 5 per cent in 2013. Meanwhile, the US proportion has dipped from 28 per cent to 23 per cent. Clinical trial enrolment in China is surging, with around 40 per cent now having more than 100 participants. Bitter pill Fewer regulatory barriers are just one of a number of reasons pharma companies are turning to China. Workers, too, are less averse to working unsociable hours than they would be in Western nations. Shirley Chen, a Barclays analyst, says: 'Chinese scientists may be happier to accept very long work hours and people like hospital personnel [where trials take place] are actually okay to do night shifts.' Major drug giants are now scouring China for potential deals. The likes of GSK, AstraZeneca and Merck have all struck deals worth more than $US1 billion to get the rights to develop and sell Chinese drugs outside the country. The rise of China's pharmaceutical industry has started to raise alarm bells in the US. Trump may be focused on returning manufacturing jobs to the US, yet some say he should be concerned that more high-quality jobs and research posts are starting to drift to China. 'Five years ago, US pharmaceutical companies didn't license any new drugs from China,' Scott Gottlied, the former Food and Drug Administration commissioner, wrote earlier this month. 'By 2024, one third of their new compounds were coming from Chinese biotechnology firms.' He warned that the shift of clinical trials to Asia could undermine innovation in the US as companies choose to 'divert funds that might otherwise bolster innovation hubs such as Boston's Kendall Square or North Carolina's Research Triangle'. Loading 'The US biotechnology industry was the world's envy, but if we're not careful, every drug could be made in China.' While Trump exempted most countries' pharmaceutical industries from tariffs in his 'liberation day' blitz, China was not spared. That means physically manufacturing drugs for the US in China is out of the question, for now at least.
